SEC approves Phase 1 trial of Bharat Biotech s COVID-19 nasal vaccine
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday recommended Bharat Biotech s intranasal vaccine for conducting phase 1 clinical trials for the coronavirus
BusinessToday.In | January 19, 2021 | Updated 22:10 IST
Bharat Biotech s intranasal vaccine for COVID-19 gets nod for Phase 1 trails
Bharat Biotech s intranasal vaccine for COVID-19 has received preliminary approval for Phase I clinical trials. The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday recommended Bharat Biotech s intranasal vaccine for conducting phase 1 clinical trials for the coronavirus. The final decision will be taken by the Drugs Controller General of India.
Photo by Jakayla Toney on Unsplash
A global study of the new coronavirus variant, 501Y.V2, shows that the virus may be resistant to existing vaccines. As scientists warn of increased infections due to the variant, South Africa records hospital admissions doubling in second wave, while the coronavirus also transmits much faster.
A comprehensive study of the coronavirus variant 501Y.V2 could evade the anti-bodies Covid-19 survivors developed during the first wave of the pandemic.
This means those who contracted Covid-19 earlier in the pandemic could be re-infected with the new variant, even though their bodies built up immunity to the earlier strain of the virus.
Measuring mitochondrial DNA could predict who will need ICU care, intubation
January 15, 2021 SHARE A new study from Washington University School of Medicine in St. Louis suggests that measuring mitochondrial DNA in the blood of patients with COVID-19 can help predict which patients are at highest risk of severe disease, requiring more intensive care. Mitochondrial DNA levels are a measure of tissue damage. Pictured are damaged mitochondria (dark grey areas) released from human lungs. The small dark dots surrounding the mitochondria are magnetic beads that carry antibodies used to isolate and study unhealthy mitochondria that have been released from dying tissues. (Image: Wandy Beatty)
New Blood Test Predicts COVID-9 Recovery by Karishma Abhishek on January 17, 2021 at 6:27 PM
Developing sudden failure of organs that leads to various complications like respiratory or kidney inefficiency or requiring other intensive care remains one of the challenging aspects of COVID-19 that may cause death even in young patients.
With an aim to explore which hospitalized patients can get into such complications, involving nearly 100 patients newly admitted to the hospital with COVID-19, a simple and rapid blood test has been formulated by scientists at Washington University School of Medicine in St. Louis.
Within a day of a hospital admission, this blood test can predict the risk of patients with COVID-19 who are highly prone to develop severe complications or death, published in the journal JCI Insight.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.